4DMT Announces New Employment Inducement Grants

Rhea-AI Summary

4D Molecular Therapeutics (Nasdaq: FDMT) announced that on February 10, 2026 its compensation committee granted 124,200 Restricted Stock Units (RSUs) to nine new non-executive employees under the Company’s 2025 Employment Inducement Award Plan.

The awards were made pursuant to Rule 5635(c)(4) of The Nasdaq Global Market to induce new employees to join the company.

News Market Reaction – FDMT

+1.39%

2 alerts

+1.39% Session close to close

$497.33M Market Cap

0.0x Rel. Volume

In the Feb 17 session, FDMT gained 1.39%, reflecting a mild positive market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details routine equity inducement grants totaling 124,200 RSUs to nine new non-exe...

Analysis

This announcement details routine equity inducement grants totaling 124,200 RSUs to nine new non-executive employees under a Nasdaq-compliant inducement plan. It adds a modest layer of future share issuance alongside existing warrant and option structures disclosed in recent filings. Investors may track how ongoing clinical milestones, corporate updates, and future equity awards interact with FDMT’s position above its 200-day MA of $7.16 and below its 52-week high.

Key Figures

Restricted Stock Units: 124,200 RSUs New employees: 9 employees Plan year: 2025 +1 more

4 metrics

Restricted Stock Units 124,200 RSUs Granted to nine new non-executive employees on Feb 10, 2026

New employees 9 employees Recipients of RSU inducement grants

Plan year 2025 Employment Inducement Award Plan used for grants

Rule cited Rule 5635(c)(4) Nasdaq rule governing inducement equity grants

Historical Context

5 past events · Latest: Feb 09 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Feb 09	Phase 3 enrollment	Positive	+1.0%	Completion of enrollment for Phase 3 4FRONT-1 trial in wet AMD.
Jan 07	Corporate update	Positive	+8.1%	2026 milestones update and cash runway into H2 2028 highlighted.
Dec 17	Clinical data update	Positive	-20.1%	Positive interim Phase 1 AEROW data for 4D-710 in cystic fibrosis.
Dec 12	Inducement grants	Neutral	+1.0%	RSU grants to new non-executive employees under inducement plan.
Dec 08	Conference appearance	Neutral	+3.5%	Announcement of presentation at J.P. Morgan Healthcare Conference.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

News has generally seen aligned reactions, though one positive clinical update coincided with a sharp negative move, suggesting occasional profit-taking or de-risking on good data.

Recent Company History

Over recent months, FDMT has highlighted advancing late-stage retinal and cystic fibrosis programs, corporate updates, and routine corporate events. Positive Phase 3 enrollment progress and a 2026 milestones update previously saw modest to strong positive moves. A positive Phase 1 interim dataset, however, was followed by a sharp decline, contrasting with other aligned reactions to conference and employment-related announcements. Today’s employment inducement grants fit the pattern of routine corporate equity awards, against a backdrop of prior clinical and corporate milestones and warrant restructurings.

Key Terms

restricted stock units, rsus, employment inducement award plan, nasdaq global market

4 terms

restricted stock units financial

"granted nine new non-executive employees 124,200 Restricted Stock Units (RSUs)"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

rsus financial

"granted nine new non-executive employees 124,200 Restricted Stock Units (RSUs)"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

employment inducement award plan financial

"pursuant to the Company’s 2025 Employment Inducement Award Plan, as amended"

An employment inducement award plan is a company program that grants stock, stock options, or other equity-based incentives to recruit or retain a specific new employee, similar to offering a signing bonus but paid in company shares. Investors watch these plans because they can dilute existing ownership, change management incentives, and increase compensation expense, all of which can affect share value and future company performance.

nasdaq global market regulatory

"under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants"

The Nasdaq Global Market is a section of the stock exchange where larger, well-established companies are listed and publicly traded. It functions like a marketplace where investors can buy and sell shares of these companies, providing them with access to capital and opportunities for growth. Its role is important because it helps investors identify and invest in reputable companies with strong financial backgrounds.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

EMERYVILLE, Calif., Feb. 13, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on February 10, 2026, the compensation committee of the Company’s board of directors granted nine new non-executive employees 124,200 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company’s 2025 Employment Inducement Award Plan, as amended, under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.

About 4DMT

4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company’s lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company’s lead indication for 4D-150 is wet age-related macular degeneration, which is currently in Phase 3 development, and second indication is diabetic macular edema. The Company’s second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.

All of the Company’s product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety or effectiveness of the Company’s product candidates for the therapeutic uses for which they are being studied.

Learn more at www.4DMT.com and follow us on LinkedIn.

Contacts:

Media:

Jenn Gordon
dna Communications
Media@4DMT.com

Investors:

Julian Pei
Head of Investor Relations and Strategic Finance
Investor.Relations@4DMT.com

FAQ

What RSU grants did 4D Molecular Therapeutics (FDMT) announce on February 13, 2026?

The company announced grants of 124,200 RSUs to nine new non-executive employees. According to the company, the awards were made on February 10, 2026 under the 2025 Employment Inducement Award Plan to induce new hires.

How many employees received inducement awards from FDMT and when were they granted?

Nine new non-executive employees received inducement RSU awards. According to the company, the compensation committee granted the awards on February 10, 2026 under the company’s inducement plan.

Under which plan and Nasdaq rule were FDMT’s February 2026 RSU grants made?

The RSU grants were made under the 2025 Employment Inducement Award Plan and pursuant to Rule 5635(c)(4) of The Nasdaq Global Market. According to the company, this rule permits inducement equity grants for new hires.

Do FDMT’s inducement RSU grants on February 10, 2026 affect current shareholders?

The announcement details the grant of 124,200 RSUs but does not quantify dilution or share impact. According to the company, the awards were granted to induce employment; investors should check filings for any dilution metrics.

Are FDMT’s February 2026 RSU awards for executives or non-executive employees?

The awards were granted to nine non-executive employees, not executives. According to the company, these inducement RSUs were intended to recruit new staff under the 2025 inducement plan.

Why did FDMT use Rule 5635(c)(4) for the February 2026 equity grants?

FDMT used Rule 5635(c)(4) to permit equity grants that induce newly hired employees. According to the company, the grants were made under that Nasdaq rule as part of the 2025 Employment Inducement Award Plan.